Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.89
BIIB's Cash to Debt is ranked lower than
85% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. BIIB: 0.89 )
Ranked among companies with meaningful Cash to Debt only.
BIIB' s Cash to Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.50 Max: N/A
Current: 0.89
Equity to Asset 0.48
BIIB's Equity to Asset is ranked lower than
71% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BIIB: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
BIIB' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.75 Max: 0.84
Current: 0.48
0.51
0.84
Interest Coverage 137.77
BIIB's Interest Coverage is ranked lower than
78% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 137.77 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 19.25  Med: 43.52 Max: 488.91
Current: 137.77
19.25
488.91
F-Score: 7
Z-Score: 5.90
M-Score: -2.77
WACC vs ROIC
5.68%
32.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 45.44
BIIB's Operating margin (%) is ranked higher than
95% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. BIIB: 45.44 )
Ranked among companies with meaningful Operating margin (%) only.
BIIB' s Operating margin (%) Range Over the Past 10 Years
Min: 9.74  Med: 29.61 Max: 40.77
Current: 45.44
9.74
40.77
Net-margin (%) 32.95
BIIB's Net-margin (%) is ranked higher than
93% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. BIIB: 32.95 )
Ranked among companies with meaningful Net-margin (%) only.
BIIB' s Net-margin (%) Range Over the Past 10 Years
Min: 6.63  Med: 21.74 Max: 30.25
Current: 32.95
6.63
30.25
ROE (%) 32.25
BIIB's ROE (%) is ranked higher than
97% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. BIIB: 32.25 )
Ranked among companies with meaningful ROE (%) only.
BIIB' s ROE (%) Range Over the Past 10 Years
Min: 2.34  Med: 16.72 Max: 30.21
Current: 32.25
2.34
30.21
ROA (%) 20.50
BIIB's ROA (%) is ranked higher than
96% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. BIIB: 20.50 )
Ranked among companies with meaningful ROA (%) only.
BIIB' s ROA (%) Range Over the Past 10 Years
Min: 1.83  Med: 11.74 Max: 22.42
Current: 20.5
1.83
22.42
ROC (Joel Greenblatt) (%) 143.86
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. BIIB: 143.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIIB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 12.99  Med: 66.06 Max: 183.46
Current: 143.86
12.99
183.46
Revenue Growth (3Y)(%) 25.70
BIIB's Revenue Growth (3Y)(%) is ranked higher than
82% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. BIIB: 25.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIIB' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -13.9  Med: 24.00 Max: 84.7
Current: 25.7
-13.9
84.7
EBITDA Growth (3Y)(%) 31.80
BIIB's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. BIIB: 31.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIIB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.4  Med: 29.00 Max: 86
Current: 31.8
-16.4
86
EPS Growth (3Y)(%) 34.90
BIIB's EPS Growth (3Y)(%) is ranked higher than
87% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. BIIB: 34.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIIB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.5  Med: 30.25 Max: 201
Current: 34.9
-65.5
201
» BIIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

BIIB Guru Trades in Q1 2015

Vanguard Health Care Fund 339,100 sh (New)
Richard Snow 2,500 sh (New)
John Burbank 46,268 sh (New)
Steven Cohen 8,800 sh (New)
Signature Select Canadian Fund 5,500 sh (New)
RS Investment Management 27,197 sh (+2132.92%)
Ray Dalio 20,446 sh (+34.99%)
Ken Fisher 81,058 sh (+2.28%)
Frank Sands 5,009,615 sh (+0.71%)
Ron Baron 9,144 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 4,932 sh (-0.06%)
Pioneer Investments 18,472 sh (-0.65%)
Murray Stahl 8,448 sh (-0.81%)
Mairs and Power 1,120 sh (-1.75%)
PRIMECAP Management 16,558,763 sh (-3.56%)
Jeremy Grantham 669,145 sh (-3.87%)
Stanley Druckenmiller 175,000 sh (-51.31%)
Jim Simons 30,300 sh (-53.50%)
Paul Tudor Jones 4,880 sh (-82.44%)
» More
Q2 2015

BIIB Guru Trades in Q2 2015

Andreas Halvorsen 513,444 sh (New)
Vanguard Health Care Fund 1,780,330 sh (+425.02%)
Richard Snow 10,500 sh (+320.00%)
Jim Simons 105,261 sh (+247.40%)
RS Investment Management 29,507 sh (+8.49%)
Ron Baron 9,144 sh (unchged)
Steven Cohen Sold Out
Stanley Druckenmiller Sold Out
Ray Dalio Sold Out
John Burbank Sold Out
Ken Fisher 80,932 sh (-0.16%)
PRIMECAP Management 16,501,541 sh (-0.35%)
Pioneer Investments 18,360 sh (-0.61%)
Murray Stahl 8,333 sh (-1.36%)
Mairs and Power 1,095 sh (-2.23%)
Mario Gabelli 4,797 sh (-2.74%)
Frank Sands 4,732,945 sh (-5.52%)
Jeremy Grantham 251,045 sh (-62.48%)
Paul Tudor Jones 600 sh (-87.70%)
» More
Q3 2015

BIIB Guru Trades in Q3 2015

Steven Cohen 6,800 sh (New)
John Burbank 10,551 sh (New)
Ray Dalio 14,766 sh (New)
Joel Greenblatt 9,410 sh (New)
Richard Snow 45,861 sh (+336.77%)
Vanguard Health Care Fund 3,666,723 sh (+105.96%)
Signature Select Canadian Fund 7,900 sh (+43.64%)
Ken Fisher 112,448 sh (+38.94%)
Ron Baron 11,814 sh (+29.20%)
Mairs and Power 1,095 sh (unchged)
Mario Gabelli 4,797 sh (unchged)
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
RS Investment Management Sold Out
Pioneer Investments Sold Out
PRIMECAP Management 15,843,460 sh (-3.99%)
Murray Stahl 7,713 sh (-7.44%)
Frank Sands 4,121,400 sh (-12.92%)
Jeremy Grantham 179,221 sh (-28.61%)
Jim Simons 34,961 sh (-66.79%)
» More
Q4 2015

BIIB Guru Trades in Q4 2015

Jeff Auxier 7,195 sh (New)
Vanguard Health Care Fund 3,810,023 sh (+3.91%)
Mario Gabelli 4,805 sh (+0.17%)
Ken Fisher 110,475 sh (-1.75%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Biogen Inc

Jean Hynes Finds Her Pot of Gold In the 3rd quarter, Vanguard Health Care Fund doubled stake in Biogen
The Vanguard Health Care Fund doubled its stake in Biogen Inc. (NASDAQ:BIIB), one of the world’s leading biotechnology companies, in the third quarter. Read more...
Vanguard Raises Stakes in Biogen, Mylan, Merck Fund buys no new stakes in 3rd quarter
As its name suggests, Vanguard Health Care Fund (Trades, Portfolio) is almost exclusively interested in health care companies. It bought no new stakes in the third quarter, but it did make additions to several existing stakes. Read more...
Biogen Among Murray Stahl's Holdings With Growing Earnings The biotechnology company's EPS has grown 28% over past five years
Murray Stahl (Trades, Portfolio) is the chairman of Horizon Asset Management Inc. He is also director of Research and co-portfolio manager of the Small Cap Opportunities Fund and the Paradigm Fund. Read more...
PRIMECAP Sells Portions of Its Top Two Stakes
Pasadena, California-based PRIMECAP Management (Trades, Portfolio) was founded in September 1983 as an independent investment management company. It evaluates securities based on their outlook over three to five years, longer if warranted. The Vanguard PRIMECAP Fund, one of the funds it manages, logged a return of 18.72% in 2014. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 16.40
BIIB's P/E(ttm) is ranked higher than
78% of the 372 Companies
in the Global Biotechnology industry.

( Industry Median: 29.14 vs. BIIB: 16.40 )
Ranked among companies with meaningful P/E(ttm) only.
BIIB' s P/E(ttm) Range Over the Past 10 Years
Min: 11.74  Med: 27.65 Max: 467.75
Current: 16.4
11.74
467.75
Forward P/E 12.38
BIIB's Forward P/E is ranked higher than
67% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 16.75 vs. BIIB: 12.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.40
BIIB's PE(NRI) is ranked higher than
76% of the 272 Companies
in the Global Biotechnology industry.

( Industry Median: 31.25 vs. BIIB: 16.40 )
Ranked among companies with meaningful PE(NRI) only.
BIIB' s PE(NRI) Range Over the Past 10 Years
Min: 11.73  Med: 27.65 Max: 530.11
Current: 16.4
11.73
530.11
P/B 5.96
BIIB's P/B is ranked lower than
81% of the 1123 Companies
in the Global Biotechnology industry.

( Industry Median: 2.60 vs. BIIB: 5.96 )
Ranked among companies with meaningful P/B only.
BIIB' s P/B Range Over the Past 10 Years
Min: 1.71  Med: 3.40 Max: 9.6
Current: 5.96
1.71
9.6
P/S 5.39
BIIB's P/S is ranked higher than
66% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. BIIB: 5.39 )
Ranked among companies with meaningful P/S only.
BIIB' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 6.08 Max: 11.93
Current: 5.39
2.8
11.93
PFCF 19.38
BIIB's PFCF is ranked higher than
67% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.57 vs. BIIB: 19.38 )
Ranked among companies with meaningful PFCF only.
BIIB' s PFCF Range Over the Past 10 Years
Min: 10.04  Med: 22.60 Max: 39.13
Current: 19.38
10.04
39.13
POCF 16.34
BIIB's POCF is ranked higher than
68% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 25.81 vs. BIIB: 16.34 )
Ranked among companies with meaningful POCF only.
BIIB' s POCF Range Over the Past 10 Years
Min: 7.83  Med: 18.21 Max: 35.24
Current: 16.34
7.83
35.24
EV-to-EBIT 12.02
BIIB's EV-to-EBIT is ranked higher than
67% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 20.78 vs. BIIB: 12.02 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.1  Med: 19.20 Max: 68.3
Current: 12.02
8.1
68.3
EV-to-EBITDA 10.70
BIIB's EV-to-EBITDA is ranked higher than
68% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 17.31 vs. BIIB: 10.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.6  Med: 15.50 Max: 27
Current: 10.7
6.6
27
PEG 0.64
BIIB's PEG is ranked higher than
87% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. BIIB: 0.64 )
Ranked among companies with meaningful PEG only.
BIIB' s PEG Range Over the Past 10 Years
Min: 0.33  Med: 1.10 Max: 48.49
Current: 0.64
0.33
48.49
Shiller P/E 43.60
BIIB's Shiller P/E is ranked higher than
57% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 49.55 vs. BIIB: 43.60 )
Ranked among companies with meaningful Shiller P/E only.
BIIB' s Shiller P/E Range Over the Past 10 Years
Min: 35.55  Med: 74.76 Max: 119.73
Current: 43.6
35.55
119.73
Current Ratio 3.52
BIIB's Current Ratio is ranked lower than
57% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. BIIB: 3.52 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 3.44 Max: 17.39
Current: 3.52
0.78
17.39
Quick Ratio 3.17
BIIB's Quick Ratio is ranked lower than
58% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BIIB: 3.17 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 3.07 Max: 16.79
Current: 3.17
0.7
16.79
Days Inventory 253.51
BIIB's Days Inventory is ranked lower than
79% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. BIIB: 253.51 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 211.91  Med: 234.74 Max: 266.3
Current: 253.51
211.91
266.3
Days Sales Outstanding 41.61
BIIB's Days Sales Outstanding is ranked higher than
71% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. BIIB: 41.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 44.30 Max: 48.62
Current: 41.61
39.79
48.62
Days Payable 73.93
BIIB's Days Payable is ranked higher than
62% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. BIIB: 73.93 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 71.43  Med: 105.99 Max: 148.21
Current: 73.93
71.43
148.21

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 21.29
BIIB's Price/Tangible Book is ranked lower than
90% of the 1051 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. BIIB: 21.29 )
Ranked among companies with meaningful Price/Tangible Book only.
BIIB' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.91  Med: 6.51 Max: 48.16
Current: 21.29
0.91
48.16
Price/Projected FCF 2.66
BIIB's Price/Projected FCF is ranked higher than
58% of the 298 Companies
in the Global Biotechnology industry.

( Industry Median: 3.18 vs. BIIB: 2.66 )
Ranked among companies with meaningful Price/Projected FCF only.
BIIB' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 2.22 Max: 25.99
Current: 2.66
0.65
25.99
Price/DCF (Earnings Based) 0.58
BIIB's Price/DCF (Earnings Based) is ranked higher than
98% of the 41 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. BIIB: 0.58 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.91
BIIB's Price/Median PS Value is ranked higher than
50% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. BIIB: 0.91 )
Ranked among companies with meaningful Price/Median PS Value only.
BIIB' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.19  Med: 0.97 Max: 5.27
Current: 0.91
0.19
5.27
Price/Peter Lynch Fair Value 0.65
BIIB's Price/Peter Lynch Fair Value is ranked higher than
85% of the 111 Companies
in the Global Biotechnology industry.

( Industry Median: 2.44 vs. BIIB: 0.65 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BIIB' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.44  Med: 1.31 Max: 20.5
Current: 0.65
0.44
20.5
Price/Graham Number 3.20
BIIB's Price/Graham Number is ranked lower than
61% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. BIIB: 3.20 )
Ranked among companies with meaningful Price/Graham Number only.
BIIB' s Price/Graham Number Range Over the Past 10 Years
Min: 0.5  Med: 3.16 Max: 22.2
Current: 3.2
0.5
22.2
Earnings Yield (Greenblatt) (%) 8.30
BIIB's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. BIIB: 8.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIIB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 5.20 Max: 12.3
Current: 8.3
1.5
12.3
Forward Rate of Return (Yacktman) (%) 32.20
BIIB's Forward Rate of Return (Yacktman) (%) is ranked higher than
81% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. BIIB: 32.20 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIIB' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -4.6  Med: 25.20 Max: 45.3
Current: 32.2
-4.6
45.3

More Statistics

Revenue(Mil) $10764
EPS $ 15.31
Beta0.51
Short Percentage of Float1.21%
52-Week Range $248.16 - 480.18
Shares Outstanding(Mil)222.90

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 11,313 12,063 13,013
EPS($) 18.43 20.35 22.30
EPS without NRI($) 18.43 20.35 22.30

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, CELG, CMXHY » details
Traded in other countries:IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Biogen Idec Inc was formed as a California corporation in 1985 and became a Delaware corporation in 1985. The Company is a biotechnology company. It discovers, develops, manufactures and markets therapies for the treatment of autoimmune disorders, neurodegenerative diseases and hemophilia. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has advanced the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.
» More Articles for BIIB

Headlines

Articles On GuruFocus.com
Jean Hynes Finds Her Pot of Gold Jan 07 2016 
Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
Biogen Among Murray Stahl's Holdings With Growing Earnings Nov 11 2015 
Biogen Is a Bargain Oct 29 2015 
Market Has Overreacted in Biogen Oct 14 2015 
Frank Sands' Undervalued Holdings With Growing EPS Oct 12 2015 
The Undervalued Stocks Among Richard Snow's Recent Buys Sep 17 2015 
The Best Companies of the Pharmaceuticals Industry – August 2015 Aug 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Investment Strategies for the Bullish Biotech Sector Jun 01 2015 

More From Other Websites
​Sanofi Genzyme revenues grow 20% in 2015 to top $4B Feb 09 2016
#1 Rated Biotech Analyst on the Sell-Off Feb 08 2016
AGTC Announces Financial Results for the Quarter Ended December 31, 2015 Feb 08 2016
Avoid biotech until elections? Analyst's view Feb 08 2016
Biogen joins international effort to share preclinical data Feb 08 2016
Biogen Joins Pioneering Target Validation Collaboration Feb 08 2016
Biogen Joins Pioneering Target Validation Collaboration Feb 08 2016
Biogen (BIIB) Stock Gets ‘Market Perform’ Rating at Leerink Feb 05 2016
​Three things Biogen is more worried about this year than it was in 2015 Feb 05 2016
Leerink Is Back On Board The Biotech Train Feb 05 2016
Technical Recap on Biotechnology Equities -- Biogen, Medivation, Grifols, and Agios Pharma Feb 05 2016
Biogen to Present at the Leerink Partners 5th Annual Global Healthcare Conference Feb 04 2016
It’s Time to Buy This Biotech Gem Feb 04 2016
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink Feb 04 2016
BIOGEN INC. Files SEC form 10-K, Annual Report Feb 03 2016
How Much Does Biogen Spend on Research and Development? Feb 03 2016
Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention Feb 03 2016
Insight into the Performance of Interferon and Other Products Feb 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK